SS Innovations International Inc. (NASDAQ: SSII) is building a position in telerobotic surgery as remote procedures gain traction, according to a recent MedTech Dive report. The company’s SSi Mantra system has been used in 195 robotic telesurgeries as of Sept. 28, 2026, including cardiac procedures and long-distance operations. Its installed base reached 244 systems, up 45% from the end of 2025, and cumulative procedures totaled 14,503. The system has expanded into 12 countries, with recent cardiac-surgery programs launched in Colombia and Sri Lanka and a new program at HCG Hospital in Ahmedabad. SS Innovations is pursuing U.S. FDA clearance and European Union CE marking to enter additional international markets.
CEO Dr. Sudhir Srivastava, a cardiac surgeon, told MedTech Dive that robotic surgery is inherently a form of teleoperation and that the central technical question is how much distance can be introduced without compromising responsiveness. The MedTech Dive article, “Telerobotic surgery is advancing around the world. Will the US embrace it?,” examined the technology’s development and the regulatory and infrastructure questions surrounding remote surgery, highlighting SS Innovations alongside larger medical-device companies and emerging robotics developers (https://ibn.fm/4ZLvL).
For industry leaders, the news signals that telerobotic surgery is moving from isolated demonstrations toward broader clinical and regulatory development. SS Innovations’ progress in accumulating telesurgery experience could position it as a key player if remote procedures become mainstream. The company’s pursuit of FDA clearance and CE marking is critical because U.S. and European markets represent significant opportunities for adoption. As noted in the MedTech Dive report, the U.S. regulatory environment will play a major role in determining how quickly telerobotic surgery is embraced. The article also highlighted SS Innovations International (NASDAQ: SSII) and its founder and CEO, cardiac surgeon Dr. Sudhir Srivastava, in an increasingly relevant part of the surgical robotics market.
The growing interest in remote surgery has implications beyond SS Innovations. Telerobotic surgery could improve access to specialized care in underserved regions, reduce travel burdens for patients, and enable expert surgeons to operate across distances. However, challenges remain, including ensuring reliable low-latency connections, addressing regulatory hurdles, and building the infrastructure needed for widespread adoption. SS Innovations’ experience with long-distance operations and cardiac procedures provides valuable data points for the field.
Investors and industry watchers can follow the latest news and updates relating to SSII in the company’s newsroom at https://ibn.fm/SSII. The company’s progress in telesurgery, combined with its regulatory ambitions, makes it a notable player in the evolving surgical robotics landscape. As remote procedures gain ground, SS Innovations’ ability to scale its technology and secure approvals will be key to its competitive position.
MissionIR, a specialized communications platform, assists IR firms with syndicated content to enhance visibility of private and public companies. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution, and a full array of tailored corporate communications solutions. For more information, visit MissionIR at www.MissionIR.com. Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer.
